دورية أكاديمية
Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series
| العنوان: | Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series |
|---|---|
| المؤلفون: | Sapisochin, G., Goldaracena, N., Astete, S., Laurence, J. M., Davidson, D., Rafael, Ehab, Castells, L., Sandroussi, C., Bilbao, I., Dopazo, C., Grant, D. R., Lazaro, J. L., Caralt, M., Ghanekar, A., McGilvray, I. D., Lilly, L., Cattral, M. S., Selzner, M., Charco, R., Greig, P. D. |
| المصدر: | Annals of Surgical Oncology; 22(7), pp 2286-2294 (2015) ; ISSN: 1534-4681 |
| بيانات النشر: | Springer |
| سنة النشر: | 2015 |
| المجموعة: | Lund University Publications (LUP) |
| مصطلحات موضوعية: | Surgery, Cancer and Oncology |
| الوصف: | To identify prognostic factors after hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). We retrospectively reviewed the combined experience at Toronto General Hospital and Hospital Vall d'Hebron managing HCC recurrence after LT (n = 121) between 2000 and 2012. We analyzed prognostic factors by uni- and multi-variate analysis. Median follow-up from LT was 29.5 (range 2-129.4) months. Median follow-up from HCC recurrence was 12.2 (range 0.1-112.5) months. At recurrence, 31.4 % were treated with curative-intent treatments (surgery or ablation), 42.1 % received palliative treatment, and 26.4 % received best supportive care. The 1-, 3-, and 5-year survivals, respectively, after HCC recurrence were 75, 60, and 31 %, vs. 60, 19, and 12 %, vs. 52, 4, and 5 % (p < 0.001). By multivariate analysis, not being amenable to a curative-intent treatment [hazard ratio (HR) 4.7, 95 % confidence interval (CI) 2.7-8.3, p < 0.001], alpha-fetoprotein of a parts per thousand yen100 ng/mL at the time of HCC recurrence (HR 2.1, 95 % CI 1.3-2.3, p = 0.002) and early recurrence (< 12 months) after LT (HR 1.6, 95 % CI 1.1-2.5, p = 0.03) were found to be poor prognosis factors. A prognostic score was devised on the basis of these three independent variables. Patients were divided into three groups, as follows: good prognosis, 0 points (n = 22); moderate prognosis, 1 or 2 points (n = 84); and poor prognosis, 3 points (n = 15). The 1-, 3-, and 5-year actuarial survival for each group was 91, 50, and 50 %, vs. 52, 7, and 2 %, vs. 13, 0, and 0 %, respectively (p < 0.001). Patients with HCC recurrence after transplant amenable to curative-intent treatments can experience significant long-term survival (similar to 50 % at 5 years), so aggressive management should be offered. Poor prognosis factors after recurrence are not being amenable to a curative-intent treatment, alpha-fetoprotein of a parts per thousand yen100 ng/mL, and early (< 1 year) recurrence after LT. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://lup.lub.lu.se/record/7602039Test; http://dx.doi.org/10.1245/s10434-014-4273-6Test; wos:000355748300025; scopus:84930483026; pmid:25472651 |
| DOI: | 10.1245/s10434-014-4273-6 |
| الإتاحة: | https://doi.org/10.1245/s10434-014-4273-6Test https://lup.lub.lu.se/record/7602039Test |
| رقم الانضمام: | edsbas.B0AA23ED |
| قاعدة البيانات: | BASE |
| DOI: | 10.1245/s10434-014-4273-6 |
|---|